Table 3. Prevalence of HPV 16, HPV 18 and other high risk HPV types by age, cytology and histology at entry.
| Age | HC-II negatives | HPV 16 | HPV 18 (not HPV 16) | Other HC-II positivesa | Total |
|---|---|---|---|---|---|
| 20–24 | 1548 (60.1%) | 315 (12.2%) | 80 (3.1%) | 632 (24.6%) | 2575 (100%) |
| 25–34 | 4867 (77.6%) | 320 (5.1%) | 127 (2.0%) | 957 (15.3%) | 6271 (100%) |
| 25–34 | 6538 (89.2%) | 112 (1.5%) | 43 (0.6%) | 638 (8.7%) | 7331 (100%) |
| 45–54 | 4707 (92.2%) | 35 (0.7%) | 15 (0.3%) | 345 (6.8%) | 5102 (100%) |
| 55–64 | 3037 (94.0%) | 21 (0.7%) | 7 (0.2%) | 166 (5.1%) | 3231 (100%) |
| Cytology | |||||
| Normal | 19 154 (89.6%) | 318 (1.5%) | 143 (0.7%) | 1765 (8.2%) | 21 380 (100%) |
| Borderline | 1232 (68.9%) | 125 (7.0%) | 54 (3.0%) | 378 (21.1%) | 1789 (100%) |
| Mild | 265 (30.2%) | 152 (17.3%) | 40 (4.6%) | 421 (47.9%) | 878 (100%) |
| Moderate | 38 (14.0%) | 107 (39.5%) | 18 (6.6%) | 108 (39.9%) | 271 (100%) |
| Severe or worse | 8 (4.2%) | 101 (52.6%) | 17 (8.8%) | 66 (34.4%) | 192 (100%) |
| Histology | |||||
| CIN1 or less | 318 (40.8%) | 104 (13.3%) | 48 (6.2%) | 310 (39.7%) | 780 (100%) |
| CIN2 | 15 (7.1%) | 85 (40.1%) | 15 (7.1%) | 97 (45.7%) | 212 (100%) |
| CIN3/SCC | 7 (2.7%) | 157 (60.4%) | 14 (5.4%) | 82 (31.5%) | 260 (100%) |
| CGIN/ADCC | 3 (16.7%) | 6 (33.3%) | 6 (33.3%) | 3 (16.7%) | 18 (100%) |
| Abnormal cytology, no histology** | 1200 (64.5%) | 133 (7.1%) | 46 (2.5%) | 481 (25.9%) | 1860 (100%) |
| Total | 20 697 (84.4%) | 803 (3.3%) | 272 (1.1%) | 2738 (11.2%) | 24 510 (100%) |
SCC: squamous cell carcinoma.
CGIN: cervical glandular intraepithelial neoplasia.
ADCC: adenocarcinoma.
a
Not HPV 16 or HPV 18.
** Women with abnormal cytology at entry but no histology (abnormal cytology resolved or still being followed-up cytologically).